Acer Medical (6857) H1 2024 earnings summary

Executive summary

• Revenue for the first half of 2024 (113/1/1–6/30) was NT$25,178K, up from NT$7,315K year-over-year.

• Net loss for the period was NT$12,186K, an improvement from a net loss of NT$20,657K year-over-year.

• Gross margin increased to 68% from 54% year-over-year.

• The company acquired 100% of Acer Health Co., Ltd. for NT$2,500K in January 2024.

Financial highlights

• Operating expenses rose to NT$30,759K from NT$26,056K year-over-year.

• Basic and diluted loss per share was NT$0.80, improved from NT$1.36 year-over-year.

• Cash and cash equivalents at period end were NT$146,999K, down from NT$252,973K a year ago.

• Total assets at June 30, 2024, were NT$243,849K, compared to NT$264,537K a year ago.

• Equity at period end was NT$209,738K, down from NT$239,461K year-over-year.

Outlook and guidance

• No explicit forward-looking guidance provided, but capital management focuses on maintaining sufficient resources for the next 12 months of operations.